Court Opinion

ID: 4307860
Source: CourtListenerOpinion
Date Created: 2018-08-28 13:00:27.411754+00
Date Added: 2024-06-11T14:42:05.999568
License: Public Domain

Case: 16-16645    Date Filed: 08/28/2018   Page: 1 of 12

                                                         [DO NOT PUBLISH]

               IN THE UNITED STATES COURT OF APPEALS

                        FOR THE ELEVENTH CIRCUIT
                          ________________________

                                No. 16-16645
                          ________________________

          D.C. Docket Nos. 4:08-md-02004-CDL; 4:13-cv-00400-CDL

In re: Mentor Corp. Obtape Transobturator Sling Products Liability Litigation.

__________________________________________________________________

PATRICIA PERRYMAN,

                                                              Plaintiff - Appellant,

                                      versus

MENTOR WORLDWIDE LLC,

                                                             Defendant - Appellee.

                          ________________________

                   Appeal from the United States District Court
                       for the Middle District of Georgia
                         ________________________

                                (August 28, 2018)
               Case: 16-16645       Date Filed: 08/28/2018      Page: 2 of 12

Before TJOFLAT and JULIE CARNES, Circuit Judges, and KAPLAN, * District
Judge.

JULIE CARNES, Circuit Judge:

       To treat the stress urinary incontinence of plaintiff Patricia Perryman

(“Plaintiff”), her doctor surgically implanted one of Mentor Worldwide LLC’s

ObTape vaginal mesh products. Post-surgery, Plaintiff experienced a number of

symptoms, including pain, tenderness, and infections, all of which were known

side effects of mesh implants. Notwithstanding repeated visits to her doctor, as

well as excisions of mesh that had begun protruding, Plaintiff’s symptoms

persisted. As a result, she eventually had the ObTape replaced with a different

product, and her symptoms largely went away.

       Seven years later, after learning from a television commercial that her post-

operative symptoms may have been caused by defects in the ObTape, Plaintiff

filed this products liability suit against Mentor in federal court. Mentor filed a

motion for summary judgment arguing that Plaintiff’s lawsuit was time-barred

because her claim accrued by the time her ObTape implant was removed, yet

Plaintiff did not file suit until seven years later—well outside the four-year statute

of limitations period provided for by applicable Florida law. The district court

*
 Honorable Lewis A. Kaplan, Senior United States District Judge for the Southern District of
New York, sitting by designation.

                                              2
              Case: 16-16645     Date Filed: 08/28/2018   Page: 3 of 12

agreed, holding that, because Plaintiff was aware that her symptoms were related

to the implantation of the ObTape mesh by the time it was removed, her claim

accrued at that time and her subsequent lawsuit was several years too late.

      Since the district court’s ruling, however, our court has addressed this very

same statute of limitations question under Florida law. See Eghnayem v. Boston

Sci. Corp., 873 F.3d 1304 (11th Cir. 2017). We must apply the standard used in

Eghnayem for review of this particular question and, upon doing so, we conclude

that a question of fact exists as to Mentor’s defense and therefore reverse the

district court’s grant of summary judgment to Mentor.

I.    BACKGROUND

      A.     Factual Background

      In May 2005, Plaintiff’s doctor surgically implanted a Mentor ObTape

vaginal mesh “sling” to treat Plaintiff’s stress urinary incontinence. Before the

surgery, Plaintiff’s doctor explained that the surgery had inherent risks, including

bleeding, infection, urinary retention, injury to tissue, and pelvic pain. Likewise,

mesh products themselves pose inherent risks. Plaintiff was informed that even if

the mesh was properly implanted and even if there was nothing wrong with it, her

body could nonetheless reject the product, and the mesh could protrude through the

vaginal wall or cause infection. Indeed, Mentor’s Product Insert Data Sheet

                                          3
              Case: 16-16645    Date Filed: 08/28/2018   Page: 4 of 12

(essentially an informational pamphlet for doctors) indicated that “[v]aginal

erosion, urethral evocation, and infection” were possible ObTape side effects,

though they were reported “very rarely.”

      Plaintiff’s surgery itself was unremarkable, but its consequences had a

lasting impact. The surgery resolved her incontinence, but Plaintiff began

experiencing vaginal infections along with pain and discomfort in her pelvic

region. Over the course of roughly six months, Plaintiff repeatedly met with her

doctor and complained of urinary retention, infections and the resulting vaginal

discharge, and pain and tenderness during intercourse.

      On multiple occasions, her doctor inspected her vagina, observed protruding

mesh, and excised it. Despite the excisions, Plaintiff’s symptoms persisted.

Eventually, in February 2006, Plaintiff decided to switch doctors. Her new doctors

recommended removal of the ObTape.

      Accordingly, on February 17, Plaintiff’s new doctors surgically removed her

ObTape and replaced it with a different sling. The new sling was a “natural

product” made with biological material that may be more likely to integrate with

the human body than plastic synthetics like ObTape. During the surgery, one

doctor definitively concluded that Plaintiff’s ObTape had eroded through her

vaginal tissue.

                                           4
              Case: 16-16645    Date Filed: 08/28/2018    Page: 5 of 12

      Plaintiff experienced no complications from her replacement surgery.

Moreover, the infections and discharge stopped. Plaintiff believed that this

positive outcome was the result of her body accepting the new mesh material better

than it had accepted the ObTape material. Nonetheless, some portions of

Plaintiff’s ObTape sling could not be removed. As a result, Plaintiff continues to

experience some tenderness and pain.

      After her initial surgery in May 2005, Plaintiff never felt that her ObTape

implant was functioning properly. She reached this conclusion because, before

receiving the implant, she had never experienced the symptoms of discomfort,

pain, vaginal discharge, and infections that occurred after the surgery. When

Plaintiff began experiencing these symptoms post-surgery, she “didn’t know what

caused” them and thought she “was just having an allergy to” the ObTape implant

or her body was “rejecting . . . it or something.” As to why her ObTape implant

was continually protruding, she thought this was because either her “body just

wasn’t accept[ing] it or maybe . . . [she] had an infection that was keeping things

not healing right.” Altogether, Plaintiff “thought the problems were related to

[her] personally or perhaps caused by some other factor besides the mesh.”

Plaintiff never suspected that ObTape was defective or that a specific defect in her

                                          5
                Case: 16-16645       Date Filed: 08/28/2018       Page: 6 of 12

ObTape implant had caused her injuries until she saw a commercial in 2013 that

reported the existence of vaginal sling defects.

       B.      Procedural History

       Alerted by television commercials to the fact that her symptoms may have

been caused by defects in the ObTape, on September 4, 2013, Plaintiff filed a

lawsuit in federal court as part of a consolidated multidistrict litigation action

against Mentor over ObTape’s alleged defects. 1 See In re: Mentor Corp. ObTape

Transobturator Sling Prods. Liab. Litig., 588 F. Supp. 2d 1374 (J.P.M.L. 2008).

Plaintiff alleged claims based on products liability, including negligence,

fraudulent and negligent misrepresentation, breach of express and implied

warranties, and fraudulent concealment.

       After discovery, Mentor moved for summary judgment on the ground that

Plaintiff’s 2013 lawsuit was barred by Florida’s four-year products liability statute

of limitations because her claim accrued no later than February 2006, when her

ObTape implant was removed. The district court granted summary judgment to

Mentor, concluding that Plaintiff had become aware that her ObTape implant was

related to her injuries no later than February 2006. Further, because she failed to

1
  Plaintiff is a resident of Florida and the surgery implanting the ObTape sling in 2005 was
performed in Florida.

                                                6
              Case: 16-16645     Date Filed: 08/28/2018   Page: 7 of 12

exercise due diligence, she could not toll the statute of limitations period based on

a claim of fraudulent concealment. Plaintiff filed a timely appeal under 28 U.S.C.

§ 1291.

II.    STANDARD OF REVIEW

       We review the grant of summary judgment and the application of a statute of

limitations de novo. F.E.B. Corp. v. United States, 818 F.3d 681, 685 (11th Cir.

2016). In doing so, we view the evidence in the light most favorable to the

nonmoving party and draw all inferences in that party’s favor. See Anderson v.

Liberty Lobby, Inc., 477 U.S. 242, 255 (1986). To grant summary judgment, the

moving party must show “that there is no genuine dispute as to any material fact

and the movant is entitled to judgment as a matter of law.” Fed. R. Civ. P. 56(a).

An issue of fact is “‘genuine’ only if a reasonable jury, considering the evidence

presented, could find for the nonmoving party.” Atheists of Fla., Inc. v. City of

Lakeland, 713 F.3d 577, 589 (11th Cir. 2013).

III.   DISCUSSION

       This is a diversity action, meaning that the substantive law governing the

case is provided by state law. The parties agree that the Florida statute of

limitations is the applicable statute here and that Florida law controls the question

whether this statute of limitations bars Plaintiff’s claim. See Cambridge Mut. Fire

                                          7
              Case: 16-16645     Date Filed: 08/28/2018     Page: 8 of 12

Ins. Co. v. City of Claxton, 720 F.2d 1230, 1232 (11th Cir. 1983) (“[S]tate statutes

of limitations are substantive laws and must be followed by federal courts in

diversity actions.”).

      In resolving a very similar dispute, we have recently been called on to apply

Florida law to the very question before us today. In Eghnayem v. Boston Scientific

Corporation, 873 F.3d 1304 (11th Cir. 2017), the plaintiff, Eghnayem, had filed

suit under Florida law for injuries she suffered after being implanted with a vaginal

mesh device. A jury concluded that the statute of limitations did not apply because

the plaintiff was not on notice of her claim more than four years before she filed

the lawsuit. On appeal, the defendant sought reversal, arguing that, as a matter of

law, the plaintiff had been on notice of a potential claim well prior to that date and

had therefore filed beyond the limitations period. Id. at 1311–13.

      We disagreed with the defendant. First, we observed that, under Florida

law, the statute of limitations does not begin to run until “the date that the facts

giving rise to the cause of action were discovered or should have been discovered

with the exercise of due diligence.” Id. at 1323 (citing Fla. Stat. § 95.031(2)(b)).

Examining Florida caselaw, we noted that such knowledge will be attributed to a

plaintiff when the latter has “notice, through the exercise of reasonable diligence,

of the possible invasion of [her] legal rights.” Id. (internal quotation marks

                                           8
              Case: 16-16645     Date Filed: 08/28/2018     Page: 9 of 12

omitted). Such notice can be inferred if there is “an injury distinct in some way

from conditions naturally to be expected from the plaintiff’s condition, and . . .

exposure to the product in question,” with some causal connection between the

product and the injury. Id. (emphasis added) (internal quotation marks omitted).

      Fleshing out a bit more what the above words mean, we explained in

Eghnayem that Florida law looks to whether the injury was the type of injury that a

patient might expect to occur to a person in her condition even when there had

been no negligence on the part of the putative defendant. When “there is nothing

about an injury that would communicate to a reasonable lay person that the injury

is more likely a result of some failure of medical care than a natural occurrence

that can arise in the absence of medical negligence, the knowledge of the injury

itself does not necessarily trigger the running of the statute of limitations.” Id. at

1324 (internal quotation marks omitted). The key is whether the injuries suffered

after contact with a product were “sufficiently dramatic to provide notice” that

something might be wrong with the product; that is, was there a dramatic change in

the patient’s condition suggesting a product defect? Id. To better illustrate the

type of notice Florida law considered to be sufficiently “dramatic,” we discussed a

Florida case in which a child receiving leukemia medication developed

convulsions and resulting paralysis, noting that the Florida Supreme Court had

                                           9
             Case: 16-16645     Date Filed: 08/28/2018   Page: 10 of 12

found the development of these conditions to be so dramatic as to reasonably alert

the parents that something could be amiss with the medication. Id. at 1323. That

being so, the limitations period began with the onset of those symptoms. Id. We

contrasted the above factual scenario with a Florida case in which a child’s

difficulty breathing following an invasive medical procedure was not deemed to be

“so obviously unusual” that it put the parents on notice of a potential malpractice

claim. Id. at 1323–24. Notice not being conveyed by these less dramatic

symptoms, the Florida appellate court concluded that the limitations period did not

begin at the time the above symptom appeared. Id.

      The “distinct injury” requirement quoted above was key in Eghnayem.

“Because even medical treatment competently performed might cause new

unpleasant symptoms, an injury must stand out from the norm to start the statutory

clock.” Id. at 1324 (internal quotation marks omitted). In short, for a claim to

accrue, a plaintiff’s injuries must be “obviously unusual.” Id.

      Applying this framework, we held that Eghnayem’s post-mesh implant

symptoms were not “sufficiently distinct . . . from what might be expected after

vaginal surgery to put her on notice of her cause of action.” Id. Post-surgery,

                                         10
               Case: 16-16645       Date Filed: 08/28/2018      Page: 11 of 12

Eghnayem’s only new symptom was urinary incontinence. 2 Id. We observed that

incontinence—although “a more dramatic symptom than some”—“was not so

obviously unusual as to indisputably put Eghnayem on notice about her claim.” Id.

Accordingly, we affirmed the district court’s denial of the defendant’s motion for

judgment as a matter of law and concluded that “the timeliness of Eghnayem’s

action was properly a question of fact for the jury.” Id. at 1324.

       Because of its marked similarity to the facts and legal issues presented in

this case, Eghnayem dictates the same result here. See Hattaway v. McMillian, 903
F.2d 1440, 1445 n.5 (11th Cir. 1990) (“We note that as a panel we are generally

bound by prior decisions of this court unless the court sitting en banc overrules the

prior decision. . . . Of course, if subsequent decisions of . . . the Florida courts cast

doubt on our interpretation of state law, a panel would be free to reinterpret state

law in light of the new precedents.” (emphasis in original)). Plaintiff experienced

pelvic pain and discomfort, infection and vaginal discharge, and mesh protrusion.

These symptoms were acknowledged side effects of ObTape implants, mesh

implants generally, and mesh implant surgery. In other words, such symptoms

could arise from a nondefective mesh that had been implanted through surgery that

2
  Unlike Perryman—who received her mesh implant to treat incontinence—the Eghnayem
plaintiff received her mesh implant to treat “pelvic organ prolapse.” Eghnayem, 873 F.3d at
1311.

                                              11
             Case: 16-16645      Date Filed: 08/28/2018   Page: 12 of 12

was properly performed. For example, one doctor observed that Plaintiff’s eroded

mesh was a “known complication”—“not something that . . . was an unusual fact

that needed to be reported.” Thus, Plaintiff’s symptoms were not “sufficiently

distinct . . . from what might be expected after vaginal surgery to put her on notice

of her cause of action” as a matter of law. Eghnayem, 873 F.3d at 1324. Taking

all inferences in favor of Plaintiff, whether her claim had accrued by February

2006—when her ObTape implant was removed—is therefore a question of fact for

the jury.

                                   CONCLUSION

      In conclusion, Eghnayem controls this case. Acknowledging that the district

court did not have the benefit of this decision before ruling, we must nonetheless

reverse its grant of summary judgment to Mentor. Instead, a jury will be required

to decide the underlying question of fact that will determine whether Plaintiff’s

action is barred by Florida’s statute of limitations.

      REVERSED.

                                           12